Artificial heart to give new hope to heart failure patients
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Visitor information – Everything you need to know about visiting our sites.
Professor Taylor’s group was the first in the world to utilize cardiac magnetic resonance (CMR) T1 mapping techniques to quantify diffuse myocardial fibrosis in humans, where it is associated with heart failure severity.
More recent research has linked diffuse fibrosis with increased cardiac stiffness as a putative mechanism for heart failure with preserved ejection fraction (HFpEF).
The group have also published numerous studies evaluating the relationship between regional myocardial fibrosis, assessed by conventional CMR late gadolinium enhancement, and sudden cardiac death, particularly in heart failure. Future research will focus on interventional studies aimed at regressing diffuse fibrosis in HFpEF, and the role of CMR in identifying heart failure patients at high risk of sudden death.
We have also developed a novel CMR method for the quantification of atrial stasis in atrial fibrillation (AF) and have documented its relationship to conventional markers of stroke risk. Additional studies will assess the relationship between atrial stasis in AF and cardio-embolic events, as well the relationship between atrial stasis and embolic stroke of uncertain significance (ESUS).
Dr. Gutman is a cardiologist at The Alfred specialising in heart failure, transplantation and non-invasive imaging (including cardiac MRI, cardiac CT and echocardiography).
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Heart patients of the future are set to benefit from a new partnership which will bring together the combined strengths of three leading institutions in cardiovascular research and patient care.
When 43-year-old Melbourne dad Mark Wohlers suffered a cardiac arrest last year, it was the swift emergency response and an Australian-first clinical trial that gave him a second chance at life.